PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Müller, T.D. ; Blüher, M.

Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?

[Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?].

Innere Med. 64, 629-635 (2023)
Postprint DOI PMC
Open Access Green
Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbidities and weight maintenance after weight loss. To achieve these goals, a conservative treatment strategy is recommended that consists of an energy-reduced diet, increased physical activity and behavioral modifications. If individual treatment targets cannot be achieved by basic treatment, stepwise therapy intensification should be initiated including short-term very low calorie diets, pharmacotherapy or bariatric surgery. However, these treatment approaches differ with respect to average weight loss and other outcomes. There is still a large gap between the efficacy of conservative strategies and "metabolic" surgery that cannot be filled by current pharmacotherapies. However, recent advances in the development of anti-obesity medications could change the positioning of pharmacotherapies in obesity management. Here we discuss whether next-generation pharmacotherapies have the potential to become an alternative to obesity surgery in the future.
Impact Factor
Scopus SNIP
Altmetric
0.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Dual Incretin Agonists ; Glucagon-like Peptide‑1 Receptor Agonists ; Semaglutide ; Tirzepatide ; Weight Reduction; Receptor Agonist; Double-blind; Body-weight; Glp-1; Gip; Glucagon; Semaglutide; Placebo; Liraglutide; Tirzepatide
Sprache deutsch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2731-7080
e-ISSN 2731-7099
Zeitschrift Innere Medizin
Quellenangaben Band: 64, Heft: 7, Seiten: 629-635 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Heidelbergerplatz 3, Berlin, Germany
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-506501-001
G-501900-221
DOI 10.1007/s00108-023-01530-0
WOS ID 001004110100002
Scopus ID 85168385819
PubMed ID 37286802
Erfassungsdatum 2023-10-06
[➜Korrektur melden]